Regenxbio (RGNX) Share-based Compensation (2014 - 2026)
Regenxbio (RGNX) posted quarterly Share-based Compensation of $8.4 million for Q4 2025, down 12.23% year-over-year from $9.5 million in Q4 2024, and down 6.92% quarter-over-quarter from $9.0 million in Q3 2025.
Regenxbio (RGNX) Share-based Compensation (2014 - 2026) Analysis & Trends
Regenxbio's Share-based Compensation history runs 12 years deep, the most recent figure standing at $8.4 million for Q4 2025.
- In Q4 2025, Share-based Compensation fell 12.23% year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at $35.5 million (down 7.83% YoY), while the FY2025 annual figure was $47.7 million, down 20.1% from the prior year.
- Share-based Compensation for Q4 2025 stood at $8.4 million, down from $9.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $65.6 million in Q2 2025, with the low at $8.3 million in Q4 2023.
- The 5-year median for Share-based Compensation is $9.8 million (2021), against an average of $12.5 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation declined 14.31% in 2024, then soared 595.28% in 2025.
- Regenxbio's Share-based Compensation stood at $9.2 million in 2021, then gained by 2.69% to $9.4 million in 2022, then fell by 11.37% to $8.3 million in 2023, then grew by 14.44% to $9.5 million in 2024, then retreated by 12.23% to $8.4 million in 2025.
- Business Quant data shows RGNX's Share-based Compensation at $8.4 million in Q4 2025, $9.0 million in Q3 2025, and $65.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 53.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.20 Mn |
| Jun 30, 2026 | 53.20 Mn |
| Dec 31, 2025 | 8.38 Mn |
| Dec 31, 2025 | 8.38 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 65.60 Mn |
| Jun 30, 2025 | 65.60 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Sep 30, 2024 | 9.88 Mn |
| Sep 30, 2024 | 9.88 Mn |
| Jun 30, 2024 | 9.44 Mn |
| Jun 30, 2024 | 9.44 Mn |
| Mar 31, 2024 | 9.60 Mn |
| Mar 31, 2024 | 9.60 Mn |
| Dec 31, 2023 | 8.34 Mn |
| Dec 31, 2023 | 8.34 Mn |